- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05366933
Complexe B : une contre-mesure nutraceutique SANS
In this project, the investigators propose to test effectiveness of a daily nutraceutical supplement containing bioactive B vitamins to mitigate optic disc edema in astronauts. The proposed countermeasure is intended to maximize functioning of the one-carbon metabolic pathway to provide enough substrate and cofactors to overcome any genetic differences that may impact the efficiency of enzyme function. By optimizing the pathway, this will 1) optimize endothelial function by increasing eNOS coupling and nitric oxide synthesis and 2) optimize collagen firmness and elasticity in the sclera and lamina cribrosa, and 3) minimize changes in total retinal thickness during and after flight.
The protocol includes assessments of ocular health and function, along with determinants of vascular endothelial function, advanced glycation end products, and nutritional status and one carbon biochemistry. These additional measures will be critical for the further definition of the causes of optic disc edema in some astronauts after long-duration space flight, and in understanding the effect of the countermeasure. Finally, the supplemented subjects in this study will be compared against total retinal thickness data from previously flown astronauts known to have not taken supplements during their missions.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Fasting (8-h) blood samples (7.5 mL SST and 5 mL EDTA tubes, 12.5 mL total per session) will be collected approximately 180 days and 45 days before flight, and return to Earth +0-2 days and 30 days after landing.
Blood samples will be analyzed for vitamin status and one-carbon biochemistry, as previously described. One blood sample (collected before flight) will be analyzed for approximately 511 SNPs matching the profile of testing from our ongoing research related to optic disc edema. Serum samples will be analyzed for biochemistry measures evaluating endothelial function, vitamin status, and oxidative damage.
Nutritional status assessment data, including inflight dietary intake and body mass data, completed for routine medical requirements will be requested for data sharing. Inflight medical exercise log data as well as available standard measures data will also be requested for data sharing. Medication use/Med Logs will also be requested for data sharing.
Vascular function VENDYS-II (Endothelix, Inc) will be used to assess reactive hyperaemia through changes in fingertip temperature. The test consists of an automated blood pressure measurement followed by cuff occlusion of the right arm for 2 to 5 min. During this time, the fingertip temperature in the right hand decreases because of the lack of circulation in the fingertip. After the cuff is released, blood flow resumes, causing a temperature rebound in the fingertip in a manner that is proportional to vascular reactivity.
Advanced Glycation End (AGE) Products Skin autofluorescence (SAF) will be analyzed non-invasively using an AGE reader (Diagnoptics Technologies, Groningen, the Netherlands). The AGE reader illuminates a skin surface of approximately 4 cm2, guarded against surrounding light, with an excitation light source with wavelength between 300 and 429 nm. This method is based on the fluorescent properties of certain AGEs accumulated in dermal tissue.
OCT and OCT-A Optical coherence tomography (OCT) and OCT-angiography (OCT-A) scans will be acquired using the Spectralis OCT2 (Heidelberg Engineering) before, during, and after flight. The scan pattern includes 24 B-scans centered in a radial pattern over the optic nerve head, as well as a 3.5 mm circle scan surrounding the optic nerve head for assessment of retinal nerve fiber layer thickness and choroid thickness. For OCT-A, five consecutive volume scans will be obtained in these regions, each containing 216 A-scans. These images will be registered, and the consecutive B-scans will be used to calculate the decorrelation among the images to provide split-spectrum amplitude decorrelation angiography (SSADA) images. This decorrelation between consecutive B-scan images will be used to highlight locations where there is blood flow. The density of the perfused peripapillary vessels within the various layers of the retina will be calculated to create a flow density map.
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Sara Zwart, PhD
- Numéro de téléphone: 2814833753
- E-mail: sara.zwart-1@nasa.gov
Sauvegarde des contacts de l'étude
- Nom: Eden Fields
- Numéro de téléphone: 2814837864
- E-mail: eden.e.fields@nasa.gov
Lieux d'étude
-
-
Texas
-
Houston, Texas, États-Unis, 77058
- Recrutement
- Johnson Space Center
-
Contact:
- Eden Fields
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
• Must be astronauts selected for 6-12 month missions on the International Space Station
Exclusion Criteria:
• Subjects taking B-vitamin supplements
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Supplemented with B-Complex
Subjects will take a vitamin B-complex supplement before, during, and after a 6-12 month spaceflight on the International Space Station |
Vitamin B-Complex Supplement containing: 5-methyltetrahydrofolate, riboflavin 5 phosphate, pyridoxal phosphate, and methylcobalamin |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Optic Disc Edema
Délai: 6 months
|
Measure change in total retinal thickness during and after flight compared to preflight using OCT |
6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Endothelial function
Délai: 6 months
|
Assess reactive hyperemia through changes in fingertip temperature |
6 months
|
|
Advanced Glycation End Products (AGE)
Délai: 6 months
|
Skin autofluorescence (SAF) will be analyzed non-invasively using an AGE reader |
6 months
|
|
Serum folate status
Délai: 6 months
|
Vitamin status assessed from a fasting blood sample |
6 months
|
|
Red Blood Cell folate status
Délai: 6 months
|
Vitamin status assessed from a fasting blood sample |
6 months
|
|
Vitamin B6 status
Délai: 6 months
|
Vitamin status assessed from a fasting blood sample |
6 months
|
|
Vitamin B12 status
Délai: 6 months
|
Vitamin status assessed from a fasting blood sample |
6 months
|
|
Glucose
Délai: 6 months
|
Serum glucose from a fasting blood sample |
6 months
|
|
Nitric oxide
Délai: 6 months
|
Serum nitric oxide from a fasting blood sample |
6 months
|
|
tetrahydrobiopterin
Délai: 6 months
|
Serum biochemistry from a fasting blood sample |
6 months
|
|
Dihydrobiopterin
Délai: 6 months
|
Serum biochemistry from a fasting blood sample |
6 months
|
|
Oxidized glutathione
Délai: 6 months
|
Serum biochemistry from a fasting blood sample |
6 months
|
|
Total antioxidant capacity
Délai: 6 months
|
Serum biochemistry from a fasting blood sample |
6 months
|
|
Advanced glycation end products
Délai: 6 months
|
Serum biochemistry from a fasting blood sample |
6 months
|
|
Albumin
Délai: 6 months
|
Serum biochemistry from a fasting blood sample |
6 months
|
|
Glycated albumin
Délai: 6 months
|
Serum biochemistry from a fasting blood sample |
6 months
|
|
3-nitrotyrosine
Délai: 6 months
|
Serum biochemistry from a fasting blood sample |
6 months
|
|
Formate
Délai: 6 months
|
Serum biochemistry from a fasting blood sample |
6 months
|
|
MMP-2
Délai: 6 months
|
Serum biochemistry from a fasting blood sample |
6 months
|
|
MMP-9
Délai: 6 months
|
Serum biochemistry from a fasting blood sample |
6 months
|
|
TIMP-1
Délai: 6 months
|
Serum biochemistry from a fasting blood sample |
6 months
|
|
TIMP-2
Délai: 6 months
|
Serum biochemistry from a fasting blood sample |
6 months
|
|
Heparan sulfate
Délai: 6 months
|
Serum biochemistry from a fasting blood sample |
6 months
|
|
Syndecan-1
Délai: 6 months
|
Serum biochemistry from a fasting blood sample |
6 months
|
|
Glypican
Délai: 6 months
|
Serum biochemistry from a fasting blood sample |
6 months
|
|
Hyaluronan
Délai: 6 months
|
Serum biochemistry from a fasting blood sample |
6 months
|
|
Total lipid peroxides
Délai: 6 months
|
Serum biochemistry from a fasting blood sample |
6 months
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Sara R Zwart, PhD, UTMB
Publications et liens utiles
Publications générales
- Zwart SR, Laurie SS, Chen JJ, Macias BR, Lee SMC, Stenger M, Grantham B, Carey K, Young M, Smith SM. Association of Genetics and B Vitamin Status With the Magnitude of Optic Disc Edema During 30-Day Strict Head-Down Tilt Bed Rest. JAMA Ophthalmol. 2019 Oct 1;137(10):1195-1200. doi: 10.1001/jamaophthalmol.2019.3124.
- Zwart SR, Gibson CR, Gregory JF, Mader TH, Stover PJ, Zeisel SH, Smith SM. Astronaut ophthalmic syndrome. FASEB J. 2017 Sep;31(9):3746-3756. doi: 10.1096/fj.201700294. Epub 2017 May 25.
- Smith SM, Zwart SR. Spaceflight-related ocular changes: the potential role of genetics, and the potential of B vitamins as a countermeasure. Curr Opin Clin Nutr Metab Care. 2018 Nov;21(6):481-488. doi: 10.1097/MCO.0000000000000510.
- McGregor HR, Lee JK, Mulder ER, De Dios YE, Beltran NE, Kofman IS, Bloomberg JJ, Mulavara AP, Smith SM, Zwart SR, Seidler RD. Ophthalmic changes in a spaceflight analog are associated with brain functional reorganization. Hum Brain Mapp. 2021 Sep;42(13):4281-4297. doi: 10.1002/hbm.25546. Epub 2021 Jun 9.
- Laurie SS, Vizzeri G, Taibbi G, Ferguson CR, Hu X, Lee SMC, Ploutz-Snyder R, Smith SM, Zwart SR, Stenger MB. Effects of short-term mild hypercapnia during head-down tilt on intracranial pressure and ocular structures in healthy human subjects. Physiol Rep. 2017 Jun;5(11):e13302. doi: 10.14814/phy2.13302.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- NASA IRB STUDY00000448
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .